While continuous glucose monitoring is replacing the traditional meter in insulin treatment, SMBG is still largely used in non-insulin treated patients with T2D or by patients undergoing basal oral/incretin therapy. The gene discussed is INS; the disease is type 2 diabetes mellitus.